{"id":"gsk-malaria-vaccine-257049-vaccine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site pain"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The vaccine works by stimulating the body's immune system to recognize and attack the parasite, thereby preventing malaria infection. It achieves this through a combination of antigens and adjuvants that mimic the natural infection process, allowing the immune system to develop a targeted response.","oneSentence":"This vaccine induces an immune response against Plasmodium falciparum, the parasite responsible for malaria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:39:50.743Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of malaria in individuals 6 weeks of age and older"}]},"trialDetails":[{"nctId":"NCT00289185","phase":"PHASE2","title":"Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-27","conditions":"Malaria, Malaria Vaccines","enrollment":340},{"nctId":"NCT00197067","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-03-15","conditions":"Malaria","enrollment":200},{"nctId":"NCT02207816","phase":"PHASE3","title":"An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-18","conditions":"Malaria","enrollment":3084},{"nctId":"NCT00866619","phase":"PHASE3","title":"Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-27","conditions":"Malaria","enrollment":15459},{"nctId":"NCT01345240","phase":"PHASE3","title":"Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Malaria, Malaria Vaccines","enrollment":705},{"nctId":"NCT01857869","phase":"PHASE2","title":"Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-20","conditions":"Malaria","enrollment":64},{"nctId":"NCT01366534","phase":"PHASE2","title":"Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-08-10","conditions":"Malaria","enrollment":67},{"nctId":"NCT01148459","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-30","conditions":"Malaria","enrollment":200},{"nctId":"NCT00197028","phase":"PHASE2","title":"Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-08-23","conditions":"Malaria","enrollment":214},{"nctId":"NCT01323972","phase":"PHASE3","title":"Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-05-16","conditions":"Malaria","enrollment":327},{"nctId":"NCT00436007","phase":"PHASE2","title":"Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-30","conditions":"Malaria","enrollment":511},{"nctId":"NCT01231503","phase":"PHASE2","title":"Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-13","conditions":"Malaria","enrollment":480},{"nctId":"NCT00380393","phase":"PHASE2","title":"Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-03","conditions":"Malaria","enrollment":894},{"nctId":"NCT00360230","phase":"PHASE2","title":"Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-30","conditions":"Malaria","enrollment":540},{"nctId":"NCT00307021","phase":"PHASE2","title":"Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-07","conditions":"Malaria","enrollment":180},{"nctId":"NCT00443131","phase":"PHASE2","title":"Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-26","conditions":"Malaria","enrollment":36},{"nctId":"NCT00323622","phase":"PHASE2","title":"Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":"Malaria","enrollment":1737}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RTS","S/AS01E vaccine"],"phase":"phase_2","status":"active","brandName":"GSK malaria vaccine 257049 Vaccine","genericName":"GSK malaria vaccine 257049 Vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine induces an immune response against Plasmodium falciparum, the parasite responsible for malaria. Used for Prevention of malaria in individuals 6 weeks of age and older.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}